Rega Institute for Medical Research, KULeuven, Minderbroedersstraat 10, 3000 Leuven, Belgium.
Viruses. 2010 Apr;2(4):826-866. doi: 10.3390/v2040826. Epub 2010 Mar 29.
Hepatitis C virus (HCV) represents a major health burden, with an estimated 180 million chronically infected individuals worldwide. These patients are at increased risk of developing liver cirrhosis and hepatocellular carcinoma. Infection with HCV is the leading cause of liver transplantation in the Western world. Currently, the standard of care (SoC) consists of pegylated interferon alpha (pegIFN-α) and ribavirin (RBV). However this therapy has a limited efficacy and is associated with serious side effects. Therefore more tolerable, highly potent inhibitors of HCV replication are urgently needed. Both Specifically Targeted Antiviral Therapy for HCV (STAT-C) and inhibitors that are believed to interfere with the host-viral interaction are discussed.
丙型肝炎病毒（HCV）是一个主要的健康负担，全球估计有 1.8 亿慢性感染者。这些患者发生肝硬化和肝细胞癌的风险增加。HCV 感染是西方世界进行肝移植的主要原因。目前，标准治疗（SoC）包括聚乙二醇干扰素α（pegIFN-α）和利巴韦林（RBV）。然而，这种治疗方法疗效有限，并且与严重的副作用相关。因此，迫切需要更耐受、高效的 HCV 复制抑制剂。本文讨论了丙型肝炎的特异性靶向抗病毒治疗（STAT-C）和那些被认为干扰宿主-病毒相互作用的抑制剂。
